Serum uric acid level among diabetic, hypertensive and diabetic-hypertensive patients attending specialist hospital Sokoto

Bala Malam Yale; Muhammed Haruna Yeldu; Kabiru Muhammed Dallatu; Abubakar Danjuma

doi:10.30574/gscbps.2020.10.1.0010

Authors

Bala Malam Yale Department of Chemical Pathology, School of Medical Laboratory Sciences, Usmanu Danfodiyo University, PMB 2346, Sokoto, Nigeria.
Muhammed Haruna Yeldu Department of Chemical Pathology, School of Medical Laboratory Sciences, Usmanu Danfodiyo University, PMB 2346, Sokoto, Nigeria.
Kabiru Muhammed Dallatu Department of Chemical Pathology, School of Medical Laboratory Sciences, Usmanu Danfodiyo University, PMB 2346, Sokoto, Nigeria.
Abubakar Danjuma Department of Chemical Pathology, Federal Medical Center Bida, Niger State, Nigeria.

DOI:

https://doi.org/10.30574/gscbps.2020.10.1.0010

Keywords:

Uric acid, Glucose, Hypertension, Diabetes, Patients, Controls

Abstract

Elevated serum uric acid is associated with metabolic disorders such as insulin resistance, hypertension, diabetes, dyslipidaemia and also increases the risk of cardiovascular disease. This study evaluated serum uric acid and fasting plasma glucose in diabetic, hypertensive and diabetic-hypertensive patients. This study consist of 120 subjects including 30 diabetics, 30 hypertensives, 30 diabetic-hypertensive patients and 30 age- and sex-matched controls. The mean serum uric acid was significantly (p<0.001) higher in diabetic, hypertensive and diabetic-hypertensive patients when compared with those of controls. While the mean values of fasting plasma glucose were significantly (p<0.001, p=0.007 and p<0.001) higher in diabetic, hypertensive and diabetic-hypertensive patients respectively when compared with those of controls. It was concluded from the finding of this study that, serum uric acid level and fasting plasma glucose increases significantly in diabetic, hypertensive and diabetic-hypertensive patients. It is recommended that serum uric acid and plasma glucose should be included as a routine investigation for the management of these groups of individuals to avoid the risk of cardiovascular diseases.

Metrics

Metrics Loading ...

References

Baynes HW. (2015). Classification, Pathophysiology, diagnosis and management of diabetes mellitus. Journal of Diabetes and Metabolism, 6, 541.

World Health Organization. (2016). Diabetes country profiles.

Makusidi MA, Liman HM, Yakubu A, Isah MD and Jega RM. (2013). Prevalence of non-communicable diseases and its awareness among inhabitants in Sokoto metropolis: outcome of a screening program for hypertension, obesity, diabetes mellitus and overt Proteinuria. Arab Journal of Nephrology and Transplant, 6(3), 189-191.

Fowler MJ. (2008). Complications of diabetes. Clinical Diabetes, 26(2), 77-82.

World Health Organization. (1999). Diagnosis and classification of diabetes mellitus and its complications, Geneva, 1-59.

Isezuo SA. (2015).People living with hypertension. Inaugural lecture published by the central coordinating committee for Usmanu Danfodiyo University Sokoto inaugural lectures and seminars, ISBN, 978-978-900-733-2, 18-48.

Keaney PM, Whelton M, Reynolds K and Jiang H. (2004). Worldwide prevalence of Hypertension: a systemic review. Journal of Hypertension, 22, 11-19.

Khosla UM, Zharikov S and Finch JL. (2005). Hyperuricaemia induces endothelial dysfunction. Kidney International Journal, 67, 1739-1742.

Mishra A, Poonam G, Arvaid G, Surjit KV, Ajeet KC and Dharamveer S. (2017). Prevalence and association of hyperuricaemia in patients of newly diagnosed essential hypertension. International Journal of Contemporary Medical Research, 4(2), 404.

Sokoto State Business Directory (SSBD). (2007). A publication of the Commerce Department, ministry of commerce, industry and tourism, Sokoto, 14-18.

United Nations population found. (2013). Sokoto state population projection, UNFPA; Nigeria.

Imam A. (2006). Prevalence of coliforms bacteria on enviroment surface in day care centre and nursery school metropolis. MPH Dissertation; Usmanu Danfodiyo University Sokoto.

Araoye MO. (2003). Research methodology with statistics for health and social sciences NATHADEX Publishers. ODO-Okun Sawmill Ilorin, Nigeria, 115-129.

Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M and Morgenstern BZ. (1993). Human blood pressure determination by sphygmomanometer. Circulation Journal, 88(5), 2460-2465.

Human Resources and Services Administration (HRSA). (2010). Maternal Child Health Bureau and the Centers for Disease Control and Prevention. Growth Charts Training Modules.

Fossati P, Prencipe L and Berti G. (1984).Use of 3, 5-dichloro-2-hydroxyl-benzene Sulfonic acid and 4-aminophenazone Chromogenic system in direct enzymatic assay of uric acid in serum and urine. Clinical Chemistry, 26, 227-231.

Trinder P. (1969).Determination of glucose by enzymatic method. Journal of Clinical Pathology, 22(2), 161-170.

Choi HK, Mount DB and Reginato AM. (2005).Pathogenesis of gout. Annal of International Medicine, 143, 499-516.

Babikr GW, El-hussein A, Abdelraheem A, Mohammed H, Magzoub A and Almasary M. (2016). The correlation of uric acid levels with glycemic control in type 2 diabetic patients. Biomedical and Pharmacology Journal, 9(3), 105-108.

Venkateswara TM and Vanukuri NK. (2016). A Study of serum uric acid level in type 2 diabetes mellitus and its association with cardiovascular risk factors. International Archives of Integrated Medicine, 3(12), 148-155.

Galvan AQ, Natali A, Bald S, Frascerra S, Sanna G, Ciociaro D and Ferrannini, E. (1995).Effect of insulin on uric acid excretion in humans. American Journal of Physiology, 268, 1–5.

Johnson RJ, Kang D, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez IB, Herrera-Acosta J and Mazzali M. (2003). Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension, 41(7), 1-8.

Pahor M, Shorr RI, Somes GW, Cushman WC, Ferrucci L and Bailey JE. (1998). Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program. Archive of International Medicine, 158, 134-1345.

Alderman MH, Cohen H, Madhavan S and Kivlighn S. (1999). Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension, 34, 144-150.

Vakil A, Vrkariya P, Barafiwala V, Gamit K, Patel D and Doctor N. (2017). Study of serum uric acid level in hypertension. Journal of Dental and Medical Sciences, 16(4), 69-73.

Forman JP, Choi H and Curhan GC. (2007). Plasma uric acid level and risk for incident hypertension among men. Journal of American Society of Nephrology, 18, 287-92.

Talwar T, Tanwar L, Gupta M and Singal KK. (2017). Study of serum uric acid level in type 2 diabetes mellitus patients. Journal of Dental and Medical Sciences, 16(10), 83-89.

Lee PG and Halter JB. (2017). The pathophysiology of hyperglycaemia in older adults: Clinical considerations. Diabetes Care, 40, 444-452.

Saunders C, Byrne CD and Guthrie B. (2013). External validity of randomized controlled trials of glycemic control of vascular disease. Diabetes Medicine, 30, 300-308.

Poudel B, Yadav BK, Yadav BK, Kumar A, Jha B and Raut KB. (2014). Serum uric acid level in newly diagnosed essential hypertension in a Nepalese population: A hospital based cross sectional study. Asian Pacific Journal of Tropical Biomedicine, 4(1), 59-64.